SELLAS Life Sciences Group, Inc.
SLS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer indications, with lead programs including galinpepimut-S (GPS) and SLS-009.
Key risk: Clinical trial uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$2.67B
Cash Runway
55.2 moLead Asset
galinpepimut-s (Phase 3)Next Catalyst
Phase3_Topline · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials · 2 catalysts for SELLAS Life Sciences Group, Inc..
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer indications, with lead programs including galinpepimut-S (GPS) and SLS-009.
- SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer indications [sec_mda · as of 2026-08-11].
- As of June 30, 2026, the company had cash and cash equivalents of $138.4 million and an accumulated deficit of $293.0 million [sec_mda · as of 2026-08-11].
- The company has a partnership with 3D Medicines for Greater China, with $10.5 million received in upfront payments and milestones, and $191.5 million in potential future milestones remaining as of June 30, 2026 [sec_mda · as of 2026-08-11].
- Key upcoming catalysts include Phase 3 topline data for galinpepimut-S (GPS) expected around December 1, 2026, and a Phase 2 readout for SLS-009 expected around December 31, 2026 [catalyst].
- The company expects its cash and cash equivalents to fund current planned operations for at least the next twelve months from June 30, 2026 [sec_mda · as of 2026-08-11].
What works
- SELLAS has a partnership with 3D Medicines for Greater China, providing upfront payments and potential future milestones of $191.5 million as of June 30, 2026 [sec_mda · as of 2026-08-11].
- The company has sufficient cash runway, with $138.4 million in cash and equivalents as of June 30, 2026, expected to fund operations for at least the next twelve months [sec_mda · as of 2026-08-11].
- SELLAS has multiple late-stage clinical programs with near-term catalysts, including Phase 3 topline data for galinpepimut-S and Phase 2 readout for SLS-009 in late 2026 [catalyst].
What to weigh
- SELLAS has an accumulated deficit of $293.0 million as of June 30, 2026, reflecting significant historical losses [sec_mda · as of 2026-08-11].
- The company cannot reasonably estimate the timing or costs to complete development of its product candidates, or when material net cash inflows may commence [sec_mda · as of 2026-08-11].
- Future operations are highly dependent on factors including successful additional financings, revenue-generating partnerships, and regulatory approval, which are uncertain [sec_mda · as of 2026-03-19].
From the filings
Quoted directly from source documents.
SELLAS is a late-stage clinical biopharmaceutical company focused on cancer therapeutics.
“We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.”
SEC MD&A · August 11, 2026
As of June 30, 2026, SELLAS had $138.4 million in cash and equivalents and an accumulated deficit of $293.0 million.
“As of June 30, 2026, we had an accumulated deficit of $293.0 million, cash and cash equivalents of $138.3 million and restricted cash and cash equivalents of $0.1 million.”
SEC MD&A · August 11, 2026
SELLAS has a partnership with 3D Medicines with potential future milestones of $191.5 million.
“A total of $191.5 million in potential future development, regulatory, and sales milestones, not including future royalties, remains under the 3D Medicines Agreement as of June 30, 2026”
SEC MD&A · August 11, 2026
SELLAS expects its cash to fund operations for at least the next twelve months.
“We expect that our cash and cash equivalents will be sufficient to fund our current planned operations for at least the next twelve months from”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Topline · galinpepimut-s — Topline data from a randomized, open-label Phase 3 study of galinpepimut-S (GPS) maintenance monotherapy.
- 2026-12-31 · Phase2_Topline · sls009 — Phase 2 readout for SLS-009, a CDK9 inhibitor.
Risks & what to watch (3)›
Key risks
- Clinical trial uncertainty — Cannot reasonably estimate timing or costs to complete development of product candidates [sec_mda · as of 2026-08-11].
- Accumulated deficit — Accumulated deficit of $293.0 million as of June 30, 2026, indicating sustained losses [sec_mda · as of 2026-08-11].
- Dependence on partnerships — Future operations depend on revenue-generating partnerships and regulatory approval, which are uncertain [sec_mda · as of 2026-03-19].
What to watch
- Phase 3 topline data for galinpepimut-S (GPS) expected around December 1, 2026 [catalyst].
- Phase 2 readout for SLS-009 expected around December 31, 2026 [catalyst].
- Cash runway and any additional financing or partnership developments [sec_mda · as of 2026-08-11].
Sources: Catalysts · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run SELLAS Life Sciences Group, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SELLAS Life Sciences Group, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
55.2 months
D/E 0.06 · 0% dilution
Lead: Phase 3
3 candidates
2 upcoming, next in ~93d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
164
Total value held
$323.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 15,051,858 | $63.7M |
| blackrock, inc. | 12,198,410 | $51.6M |
| susquehanna international group, llp | 8,981,556 | $38.0M |
| state street corp | 8,396,356 | $35.5M |
| citadel advisors llc | 4,882,641 | $20.7M |
| geode capital management, llc | 3,912,606 | $16.6M |
| marshall wace, llp | 2,037,162 | $8.6M |
| jones financial companies lllp | 1,675,077 | $7.3M |
| vanguard portfolio management llc | 1,462,806 | $6.2M |
| morgan stanley | 1,336,293 | $5.7M |
Showing top 10 of 164 institutional holders of SELLAS Life Sciences Group, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 30.0%
- Days to cover
- 6.5
- Shares short
- 53,525,042
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SLS short interestGovernance
Frequently asked questions
What is the AI investment thesis for SELLAS Life Sciences Group, Inc.?
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer indications, with lead programs including galinpepimut-S (GPS) and SLS-009.
What is SELLAS Life Sciences Group, Inc.'s lead drug candidate?
SELLAS Life Sciences Group, Inc.'s most advanced tracked candidate is galinpepimut-s (Phase 3) for Acute Myeloid Leukemia.
What is SELLAS Life Sciences Group, Inc.'s next catalyst?
SELLAS Life Sciences Group, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth" — expected December 1, 2026.
Who is the CEO of SELLAS Life Sciences Group, Inc.?
Dr. Angelos M. Stergiou M.D., ScD h.c. is the chief executive officer of SELLAS Life Sciences Group, Inc. (SLS).
Where is SELLAS Life Sciences Group, Inc. headquartered?
SELLAS Life Sciences Group, Inc. (SLS) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.